Metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease also decreases at thyroid

Annals of Nuclear Medicine

Volumn 19, Issue 3, 2005, Pages 225-229

  Matsui, Hideaki ^a   Udaka, Fukashi ^a   Oda, Masaya ^a   Tamura, Akiko ^a   Kubori, Tamotsu ^a   Nishinaka, Kazuto ^a   Kameyama, Masakuni ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

123I labeled metaiodobenzylguanidine (MIBG); Autonomic nervous system; Parkinson's disease; Thyroid

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENERVATION; DIFFERENTIAL DIAGNOSIS; FEMALE; HEART; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SHY DRAGER SYNDROME; SYMPATHETIC NERVE; THYROID GLAND; TISSUE DISTRIBUTION;

EID: 21044451339     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984609     Document Type: Article

References (26)

1. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994; 49: 81-84.
2. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27: 566-573.
3. Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neural Sci 2000; 175: 3-12.
4. Reinhardt MJ, Jungling FD, Krause TM, Braune S. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000; 27: 595-600.
5. Orimo S. Usefulness of MIBG myocardial scintigraphy to differentiate parkinsonism and dementia with Lewy bodies. Neurol Med 2003; 58: 544-554. (in Japanese)
6. 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 2004; 18: 453-461.
7. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in parkinson's disease. Neurology 2002; 58: 1247-1255.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
9. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163: 94-98.
10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
11. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002; 58: 1247-1255.
12. Yamamoto M. Parkinson's disease: Advances in pathology and autonomic nervous system. Tokyo; Chugai Igakusha 2004. (in Japanese)
13. Dae MW, De Marco T, Botvinick EH, O'Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med 1992; 33: 1444-1450.
14. Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med 1993; 34: 57-60.
15. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989; 30: 1182-1191.
16. Sisson JC, Bolgos G, Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J 1991; 121: 1119-1123.
17. Jager WADH, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960; 23: 283-290.
18. Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986; 27: 84-89.
19. 123I-metaiodobenzylguanidine. Neurol Med 1997; 47: 158-163.
20. 123I-BMIPP single photon emission computed tomography. Jpn J Diag Imag 2002; 22: 749-759.
21. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
22. Langston JW, Forno LS. The hypothalamus in Parkinson's disease. Ann Neurol 1978; 3: 129-133.
23. Rajput AH, Rozdilsky B. Dysautonomia in parkinsonism. A clinicopathological study. J Neurol Neurosurg Psychiatry 1976; 39: 1092-1100.
24. Matthews MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In: Bannister R, Mathias CJ (eds), Autonomic failure, 3rd ed. Oxford; Oxford University Press, 1992: 593-621.
25. Chiueh CC, Zukowska-Grojec Z, Kirk KL, Kopin IJ. 6-Fluorocatecholamines as false adrenergic neurotransmitters. J Parmacol Exp Ther 1983; 225: 529-533.
26. 18F]fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function-studies in normal humans. Clin Auton Res 1997; 7: 17-29.